Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen-presenting cells

10.1038/3488 ◽  
1998 ◽  
Vol 16 (11) ◽  
pp. 1045-1049 ◽  
Author(s):  
Huang-Ge Zhang ◽  
Di Liu ◽  
Yuji Heike ◽  
PingAr Yang ◽  
Zheng Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Fas Ligand ◽  
Antigen Presenting Cells ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting

Indoleamine 2,3-dioxygenase–expressing antigen-presenting cells and peripheral T-cell tolerance

2003 ◽  
Vol 112 (5) ◽  
pp. 854-860 ◽  
Author(s):  
Dagmar von Bubnoff ◽  
Daniel Hanau ◽  
Joerg Wenzel ◽  
Osamu Takikawa ◽  
Brian Hall ◽  
...  
Keyword(s):  
T Cell ◽  
Antigen Presenting Cells ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Indoleamine 2,3 Dioxygenase ◽  
Antigen Presenting

scholarly journals A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7.

1993 ◽  
Vol 178 (5) ◽  
pp. 1789-1793 ◽  
Author(s):  
Y Wu ◽  
Y Guo ◽  
Y Liu
Keyword(s):  
T Cell ◽  
Costimulatory Molecule ◽  
T Cell Responses ◽  
Antigen Presenting Cells ◽  
Costimulatory Molecules ◽  
Cellular Distribution ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Cell Responses ◽  
Antigen Presenting

CTLA4 ligands are important costimulatory molecules because soluble CTLA4Ig blocks the induction of T cell responses and induces T cell tolerance. As CTLA4 immunoglobulin (CTLA4Ig) binds B7 when the latter is expressed on fibroblasts, it was widely assumed that CTLA4Ig blocks T cell costimulation by blocking the function of B7. Here we show that the major costimulatory ligand bound by CTLA4Ig (which we term CTLA4 ligand A) on antigen-presenting cells are not encoded by the B7 gene. CTLA4 ligand A also differs from B7 in cellular distribution and in the respective levels of expression. Both B7 and CTLA4 ligand A are critically involved in T cell costimulation.

Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

Blood ◽  
2001 ◽  
Vol 98 (4) ◽  
pp. 1070-1077 ◽  
Author(s):  
Eduardo M. Sotomayor ◽  
Ivan Borrello ◽  
Frédérique-Marie Rattis ◽  
Alex G. Cuenca ◽  
Jacob Abrams ◽  
...  
Keyword(s):  
Bone Marrow ◽  
T Cells ◽  
T Cell ◽  
B Cell ◽  
Tumor Cells ◽  
Tumor Antigen ◽  
Antigen Presenting Cells ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting

Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs.

Does T-cell tolerance require a dedicated antigen-presenting cell?

Nature ◽  
1989 ◽  
Vol 338 (6210) ◽  
pp. 74-76 ◽  
Author(s):  
Polly Matzinger ◽  
Sylvie Guerder
Keyword(s):  
T Cell ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo

10.1038/nm962 ◽  
2003 ◽  
Vol 9 (12) ◽  
pp. 1469-1476 ◽  
Author(s):  
Douglas G Millar ◽  
Kristine M Garza ◽  
Bernhard Odermatt ◽  
Alisha R Elford ◽  
Nobuyuki Ono ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Function ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

scholarly journals Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells

Blood ◽  
2008 ◽  
Vol 111 (7) ◽  
pp. 3546-3552 ◽  
Author(s):  
Christian Schütz ◽  
Martin Fleck ◽  
Andreas Mackensen ◽  
Alessia Zoso ◽  
Dagmar Halbritter ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Immune Responses ◽  
Fas Ligand ◽  
T Cell Responses ◽  
Antigen Presenting Cells ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Cytotoxic T Cell Responses ◽  
Antigen Presenting

Abstract Several cell-based immunotherapy strategies have been developed to specifically modulate T cell–mediated immune responses. These methods frequently rely on the utilization of tolerogenic cell–based antigen-presenting cells (APCs). However, APCs are highly sensitive to cytotoxic T-cell responses, thus limiting their therapeutic capacity. Here, we describe a novel bead-based approach to modulate T-cell responses in an antigen-specific fashion. We have generated killer artificial APCs (κaAPCs) by coupling an apoptosis-inducing α-Fas (CD95) IgM mAb together with HLA-A2 Ig molecules onto beads. These κaAPCs deplete targeted antigen-specific T cells in a Fas/Fas ligand (FasL)–dependent fashion. T-cell depletion in cocultures is rapidly initiated (30 minutes), dependent on the amount of κaAPCs and independent of activation-induced cell death (AICD). κaAPCs represent a novel technology that can control T cell–mediated immune responses, and therefore has potential for use in treatment of autoimmune diseases and allograft rejection.

Sign in / Sign up

Export Citation Format

Share Document